Hospitalization and Mortality in Patients With Heart Failure Treated With Sacubitril/Valsartan vs. Enalapril: A Real-World, Population-Based Study.

Front Cardiovasc Med · 2020 · PMC7855850 · PMID 33553256

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

borderline non-significantno p-value reported

Compared with enalapril, sacubitril/valsartan users were associated with a lower risk of primary composite outcome [hazard ratio (HR) 0.58; 95% confidence interval (CI), 0.45–0.75], heart failure-related hospitalization (HR 0.59; 95% CI, 0.45–0.77), all-cause mortality (HR 0.51; 95% CI, 0.36–0.74) and borderline non-significant reductions in all-cause hospitalization (HR 0.85; 95% CI, 0.70–1.04) and cardiovascular mortality (HR 0.63; 95% CI, 0.39–1.02).

also in 434 other papers

did not reach statistical significanceno p-value reported

Notably, the treatment effect of sacubitril/valsartan did not reach statistical significance for the primary outcome (HR, 1.39; 95% CI, 1.06–1.80) for the Asia-Pacific region ( 9 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.